Home LiteratureArticle Details
PMID: 32505558 Published · ppublish English

Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy.

Cirugia espanola ·Vol. 98 ·No. 10 ·2020-12-00

Allué Cabañuz M, Domingo Bretón M, Chóliz Ezquerro J, Arribas Del Amo MD, Güemes Sánchez AT

Abstract

Contralateral prophylactic mastectomy (CPM) has been reported to reduce risk of contralateral breast cancer (CBC) by at least 90%.In addition, BRCA carriers presents higher risk of ipsilateral recurrence and a second primary tumor. The aim is to evaluate risk of CBC and recurrence and to analyze predictive factors in BRCA1/2 mutation carriers and non-carriers at high-risk of hereditary breast cancer patients. Retrospective observational study. 46 patients underwent bilateral mastectomy during 2004-2018. Cohort comprised 9 patients BRCA1,12 BRCA2 and 25 at high-risk without mutation. Median follow-up 79 months. 16 patients recently diagnosed and 30 previously treated by breast cancer whom underwent CPM at second time (because of later detection of BRCA mutation in 10 cases). The external lateral incision was most frequent surgical technique. In all patients immediate reconstruction was performed. In CPM pieces, 4 in situ carcinoma, 3 invasive and 1 atypical hyperplasia were found. The incidence of occult contralateral cancer was 15.2%. Recurrence was observed in 5 patients a media of 21.2 months after surgery. FSD was 83.74 months and OS 84.33 months. Regression models identified BRCA1/2 mutation and high risk without mutation as significant occult tumor predictive factors while tumor size≥2cm was predictive of recurrence. In our series we found a10.8% recurrence despite CPM and 7 patients (15.2%) would have developed a CBC in subsequent years.

Keywords
BRCA1 BRCA2 Contralateral breast cancer Cáncer de mama contralateral Cáncer de mama hereditario Hereditary breast cancer Recurrence Recurrencia
Article Info
Journal
Cirugia espanola
Abbr.
Cir Esp (Engl Ed)
ISSN
2173-5077
Corresponding email
Published
2020-12-00
Language
English
Country/Region
Spain
NLM ID
101771152
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com